ClinicalTrials.gg
CompletedNCT02062203Updated Nov 14, 2018

Effect of AKB-6548 on Cardiac Repolarization Intervals in Healthy Volunteers

A Phase 1 interventional study of AKB-6548 (therapeutic dose) and AKB-6548 (supratherapeutic dose) in Healthy Volunteers, sponsored by Akebia Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-11-14.

Sponsored by Akebia Therapeutics · Phase 1, Interventional, and Other

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies testing vadadustat in Anemia — 1 open to participants now, 1 under way, none of them phase 3. vadadustat · Anemia.

Enrollment
16th of 27
50 · median 60
Started
2014
with 2 others
Phase 1
4 of 27
none open now
Registered
4th of 27
by date
Lead sponsor
21 of 27
Akebia Therapeutics

Among the 27 studies testing vadadustat in Anemia, this one is the 16th largest by enrollment, is one of 3 that started in 2014, is one of 4 in phase 1, and was the 4th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

1 of the 27 studies testing vadadustat in Anemia is open now. Recruiting first, the newest first:

About vadadustat

vadadustat: first FDA approval 2024 (VAFSEO), first EMA approval 2023. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing vadadustat in Anemia, or all of them as a file.
02

Study summary

The main purpose of this study is to evaluate the effect of single oral therapeutic and supratherapeutic doses of AKB-6548 on the QT interval.

03

Conditions studied

  • Healthy Volunteers

Keywords

  • Akebia
  • QT interval
  • TQT
  • pharmacokinetic
  • anemia
  • chronic kidney disease
  • CKD
  • chronic renal insufficiency
  • renal impairment
  • safety
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Key Inclusion Criteria:

  • Healthy, non-smoking males or females, 18 and 55 years of age, inclusive
  • 18.0 and 32.0 kg/m2, inclusive
  • non 12-lead
  • heart rate of 45 to 90 beats per minute, inclusive
  • mean systolic blood pressure \<141 mmHg and mean diastolic blood pressure \< 90 mmHg

Key Exclusion Criteria:

  • history or presence of significant cardiovascular, pulmonary, hepatic, renal, hematologic, GI, endocrine, immunologic, dermatologic, neurologic, or psychiatric disease
  • history of unexplained syncope, cardiac arrest, unexplained cardiac arrhythmias, or torsades de pointes, structural heart disease, or a family history of Long syndrome
  • significant abnormalities in liver function tests
  • history of stomach or intestinal surgery or resection that would potentially alter absorption and/or excretion of orally administered drugs
  • history of Gilbert's Syndrome
  • positive hepatitis panel
  • seizure disorder or receiving anti-epilepsy medication for seizure disorder
  • any acute or chronic condition that, in the opinion of the Investigator, may pose a safety risk to a subject in this study or which would limit the subject's ability to complete and/or participate in this clinical study
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
50 participants (actual)

Study arms

  • Experimental
    AKB-6548 (therapeutic dose)

    Drug: AKB-6548 (therapeutic dose)

  • Experimental
    AKB-6548 (supratherapeutic dose)

    Drug: AKB-6548 (supratherapeutic dose)

  • Placebo comparator
    Placebo

    Drug: Placebo

  • Active comparator
    Moxifloxacin

    Drug: Moxifloxacin

Interventions

06

What researchers measure

Primary outcomes

  1. Placebo-corrected change-from-baseline QTcF (ΔΔQTcF) following AKB-6548 administration.

    Time frame: multiple timepoint evaluations from pre-dose to 24 hours post-dose

Secondary outcomes

  1. Placebo-corrected change-from-baseline heart rate (HR), PR interval, QRS interval

    Time frame: multiple timepoint evaluations from pre-dose to 24 hours post-dose

  2. Categorical outliers defined as QTcF >450 msec, 480 msec and 500 msec at any timepoint and change-from-baseline QTcF (ΔQTcF) >30 msec (increased by 30 msec) and >60 msec

    Time frame: multiple timepoint evaluations from pre-dose to 24 hours post-dose

  3. Categorical outliers for HR, PR interval, QRS interval

    Time frame: multiple timepoint evaluations from pre-dose to 24 hours post-dose

  4. Frequency of T wave morphology changes

    Time frame: multiple timepoint evaluations from pre-dose to 24 hours post-dose

  5. Placebo-corrected change-from-baseline QTcF (ΔΔQTcF) following moxifloxacin administration

    Time frame: multiple timepoint evaluations from pre-dose to 24 hours post-dose

  6. Safety parameters to include adverse events; changes in routine clinical laboratory measures including chemistry, hematology, and urinalysis; and clinically significant changes noted during physical examinations or in vital signs

    Time frame: from first dose of study medication through the final protocol required visit

07

Study locations

1 site
  • Evansville, Indiana, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jan 2014, a primary completion of Apr 2014 and a completion of Apr 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2014
First posted
Feb 13, 2014
Start
Jan 2014
Primary completionActual
Apr 2014
CompletionActual
Apr 2014
Last update
Nov 14, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 14, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02062203
Responsible party
Sponsor
First posted
Feb 13, 2014
Start date
Jan 2014
Primary completion
Apr 2014
Completion
Apr 2014
Last update
Nov 14, 2018

Study contacts

Akebia Therapeutics
study director · Sponsor GmbH

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Vadadustat

Start the discussion